Results 131 to 140 of about 176,105 (240)

Health Insurance Coverage and Income Inequality in the United States: Findings from the American Community Survey, 2010 to 2023. [PDF]

Inquiry
Molina-Salazar RE, Carbajal-De-Nova C.
europepmc   +1 more source

Non‐melanoma skin cancer risk with Janus kinase inhibitors compared to interleukin‐6 receptor inhibitors in rheumatoid arthritis: results from a national cohort study

Arthritis &Rheumatology, Accepted Article.
Background Non‐melanoma skin cancer (NMSC) is one of the most common malignancies in rheumatoid arthritis (RA). This analysis assessed NMSC risk with Janus kinase inhibitors (JAKi) compared to interleukin‐6 receptor inhibitors (IL‐6Ri). Method This study used data from the British Society for Rheumatology Rheumatoid Arthritis Register (BSRBR‐RA) linked
Zixing Tian, Lianne Kearsley‐Fleet, Sizheng Steven Zhao, James Galloway, Mark Lunt, Kath Watson, Narges Azadbakht, BSRBR‐RA Contributors Group, Kimme L Hyrich   +8 more
wiley   +1 more source

Departing from standard practices: Strategic application of value engineering in the anatomy laboratory to enhance formaldehyde extraction using high‐impact, low‐cost, and low‐maintenance solutions

Anatomical Sciences Education, Volume 18, Issue 3, Page 241-253, March 2025.
Abstract This study describes the process of developing a high‐impact, low‐cost, and low‐maintenance air ventilation system for anatomy facilities. It employed the strategic application of Value Engineering (VE), assuring that the air ventilation system meets contemporary threshold limit values (TLVs) for formaldehyde in the working zone of dissection ...
Jürgen Russ, Niels Hammer
wiley   +1 more source

The causal effects of mandatory health insurance coverage expansion in Switzerland. [PDF]

Int J Health Econ Manag
Kaiser B, Kohler A, Schmid CPR.
europepmc   +1 more source

Prevalence of Phelan McDermid Syndrome Estimated To Be ~1:7300 Using a Multisource Model

Autism Research, EarlyView.
ABSTRACT Estimating the prevalence of genetic disorders is complicated by many factors including sampling bias and differing methods of estimation. However, establishing the true prevalence of these disorders is critical for understanding disease burden, pharmacoeconomic modeling, and resource allocation for testing and care.
Tess Levy, David Lapidus, Kate Friedman, Paige Siper, Larry Glass, Liza Squires, Mary Hames, Joseph D. Buxbaum, Genetic Testing Consortium, Brooklynn Gasser, Meghan Towne, Behrang Mahjani, Seulgi Jung, Stuart Schwartz, Kai Lee Yap, Mindy Li, Avinash V. Dharmadhikari, Gordana Raca, Dolores B. Estrine, Stefanie Biller, Amanda Singleton, Sarah Poll, Alexander Kolevzon   +22 more
wiley   +1 more source

Health Insurance Coverage and Access to Care Among Older Immigrants: Evidence from the National Health Interview Survey, 2020 to 2023. [PDF]

Inquiry
Rani M, Yeatts DE.
europepmc   +1 more source

The integration of the British Pharmacological Society's prescription safety assessment into the WHO 6‐step model of rational pharmacotherapy in a Turkish medical school

British Journal of Clinical Pharmacology, EarlyView.
Aims At Koç University School of Medicine, a one‐week rational pharmacotherapy (RPHM) programme, modelled after WHO 6‐step, has been introduced in the fourth‐year curriculum to improve prescription skills. For efficient problem‐based learning (PBL) sessions on a prespecified topic, students need to brush up on basic pharmacology knowledge, so we ...
Sinem Ezgi Gülmez, Gülnihal Özcan, Hakan S. Orer   +2 more
wiley   +1 more source

Sample representativeness and temporal comparability in SEAR study, and achieving equitable health insurance coverage - Authors' reply. [PDF]

Lancet Reg Health Southeast Asia
Shukla SK, John P, Singh N, Singh N.
europepmc   +1 more source

Health Insurance Coverage for Asymptomatic Seborrheic Keratoses Treatment. [PDF]

Cureus, 2023
Fernandes E, Dao H.
europepmc   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source